Trials / Completed
CompletedNCT04041843
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
A Pilot Study of an Oral Anticoagulant "Apixaban" for theTreatment of Venous Thromboembolism in Children and Adolescents
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- New York Medical College · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban | Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg |
Timeline
- Start date
- 2017-06-02
- Primary completion
- 2021-05-31
- Completion
- 2022-05-31
- First posted
- 2019-08-01
- Last updated
- 2022-10-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04041843. Inclusion in this directory is not an endorsement.